proxyvotesnow.com

Home › Companies › Madrigal Pharmaceuticals, Inc. › 2024-2025

Madrigal Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Madrigal Pharmaceuticals, Inc.’s Form 8-K, filed 2025-06-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 11Reported items
  • 331Asset managers
  • 2,737Fund votes
  • 2025-06-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Madrigal Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Madrigal Pharmaceuticals, Inc.

These tallies are Madrigal Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Madrigal Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2025-06-20
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Julian C. Baker 17,144,833---- 1,806,0701,476,517 Majority: yes
Elect Director: Raymond Cheong, Ph.D., M.D. 18,218,687---- 732,2161,476,517 Majority: yes
Elect Director: Jacqualyn A. Fouse, Ph.D. 18,845,616---- 105,2871,476,517 Majority: yes
Elect Director: Richard S. Levy, M.D. 17,734,255---- 1,216,6481,476,517 Majority: yes
Proposal 2: The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. 20,230,193179,95917,269 --0 Majority: yes
Proposal 3: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers. 18,720,175208,91121,817 --1,476,517 Majority: yes

Source: Madrigal Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-06-20 — read the filing on EDGAR.

How asset managers voted at the Madrigal Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 331 asset managers that disclosed a Madrigal Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Madrigal Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Advisory vote to approve executive compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 18,720,175AGAINST: 208,911

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”): 18,720,175 for, 208,911 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 22,187,716 outstanding shares: 84% for, 1.0% against (85% of the company cast a for/against vote).

The 328 asset managers below cast 99.3% of the shares they voted on this item FOR (17,723,343 for, 107,389 against).

FOR 99.3%
FOR: 17,723,343 (99.4%)AGAINST: 107,389 (0.6%)ABSTAIN: 4,843 (0.0%)NOT VOTED: 28 (0.0%)
Largest asset managers voting on “Advisory vote to approve executive compensation” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP1,993,6870 00For
BAKER BROS. ADVISORS LP1,974,5900 00For
Janus Henderson1,877,9930 00For
Vanguard1,833,438151 00For
JANUS INVESTMENT FUND1,404,1910 00For
State Street1,033,7420 00For
T. Rowe Price875,2420 00For
BlackRock797,7510 00For
Fidelity573,7950 00For
GEODE CAPITAL MANAGEMENT, LLC390,7230 00For
Charles Schwab307,8320 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC283,9220 00For
Woodline Partners LP272,3680 00For
Avoro Capital Advisors LLC205,4460 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.198,3910 00For
Artisan193,8420 00For
PICTET ASSET MANAGEMENT SA188,4740 00For
Rock Springs Capital Management LP166,6980 00For
Erste Asset Management GmbH164,4000 00For
ArrowMark Colorado Holdings LLC151,4610 00For
Victory Capital122,8730 00For
Fiera Capital Corp121,9360 00For
Federated Hermes116,0500 00For
ARMISTICE CAPITAL, LLC111,0440 00For
Invesco96,7540 00For

Showing the 25 largest of 328 asset managers. See all 328 in the interactive database.

2. Advisory vote to approve the frequency of future advisory votes to approve executive compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 74%1 YEAR 25%

The 309 asset managers below cast 99.9% of the shares they voted on this item FOR (110,548 for, 108 against).

FOR: 110,548 (0.6%)AGAINST: 108 (0.0%)ABSTAIN: 1,407 (0.0%)ONE YEAR: 12,714,244 (73.6%)1 YEAR: 4,375,281 (25.3%)3 YEARS: 53,931 (0.3%)THREE YEARS: 3,762 (0.0%)2 YEARS: 3,698 (0.0%)1-YEAR: 138 (0.0%)NOT VOTED: 28 (0.0%)1YEAR: 11 (0.0%)1.0: 0 (0.0%)3.0: 0 (0.0%)2.0: 0 (0.0%)
Largest asset managers voting on “Advisory vote to approve the frequency of future advisory votes to approve executive compensation” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP00 00One Year
BAKER BROS. ADVISORS LP00 001 Year
Janus Henderson00 00One Year
Vanguard00 00One Year
JANUS INVESTMENT FUND00 00One Year
State Street00 00One Year
T. Rowe Price00 00One Year
BlackRock00 001 Year
Fidelity00 00One Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Charles Schwab00 001 Year
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC00 00One Year
Woodline Partners LP00 00One Year
Avoro Capital Advisors LLC00 001 Year
Artisan00 00One Year
PICTET ASSET MANAGEMENT SA00 00One Year
Rock Springs Capital Management LP00 00One Year
ArrowMark Colorado Holdings LLC00 001 Year
Victory Capital00 00One Year
Federated Hermes00 001 Year
ARMISTICE CAPITAL, LLC00 001 Year
Invesco00 00One Year
Hood River Capital Management LLC96,4120 00For
Northern Trust00 001 Year
Goldman Sachs00 00One Year

Showing the 25 largest of 309 asset managers. See all 309 in the interactive database.

3. Re-election of Class III directors: Jacqualyn Fouse, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 18,845,616WITHHELD: 105,287

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacqualyn A. Fouse, Ph.D.”): 18,845,616 for, 105,287 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 22,187,716 outstanding shares: 85% for, 0.5% withheld (85% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (6,079,272 for, 0 against).

FOR 99.3%
FOR: 6,079,272 (99.4%)ABSTAIN: 39,018 (0.6%)
Largest asset managers voting on “Re-election of Class III directors: Jacqualyn Fouse, Ph.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 1510For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price369,8820 00For
State Street360,4140 00For
BlackRock330,9400 00For
Erste Asset Management GmbH164,4000 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable50,3360 00For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust36,7930 00For
Brighthouse33,6430 1,4070For
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial23,5000 00For
MERIDIAN FUND INC23,4770 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

4. Re-election of Class III directors: Julian Baker

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 17,144,833WITHHELD: 1,806,070

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Julian C. Baker”): 17,144,833 for, 1,806,070 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 22,187,716 outstanding shares: 77% for, 8% withheld (85% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (5,078,397 for, 0 against).

FOR 83%ABSTAIN 17%
FOR: 5,078,397 (83.0%)ABSTAIN: 1,039,893 (17.0%)
Largest asset managers voting on “Re-election of Class III directors: Julian Baker” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 1510For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price00 369,8820Abstain
State Street1,5390 358,8750Abstain
BlackRock330,9400 00For
Erste Asset Management GmbH164,4000 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes00 58,0250Abstain
Goldman Sachs54,4140 00For
Jackson National12,7620 38,2670Abstain
Equitable27,6120 22,7240For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco00 42,4920Abstain
Bridge Builder Trust27,8900 8,9030For
Brighthouse6,4950 28,5550Abstain
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial4,1010 19,3990Abstain
MERIDIAN FUND INC23,4770 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

5. Re-election of Class III directors: Raymond Cheong, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 18,218,687WITHHELD: 732,216

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Raymond Cheong, Ph.D., M.D.”): 18,218,687 for, 732,216 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 22,187,716 outstanding shares: 82% for, 3% withheld (85% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (5,648,016 for, 0 against).

FOR 92%8%
FOR: 5,648,016 (92.3%)ABSTAIN: 470,274 (7.7%)
Largest asset managers voting on “Re-election of Class III directors: Raymond Cheong, M.D., Ph.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 1510For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price00 369,8820Abstain
State Street360,4140 00For
BlackRock330,9400 00For
Erste Asset Management GmbH164,4000 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable27,6120 22,7240For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust27,8900 8,9030For
Brighthouse25,7150 9,3350For
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial17,3750 6,1250For
MERIDIAN FUND INC23,4770 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

6. Re-election of Class III directors: Richard Levy, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 17,734,255WITHHELD: 1,216,648

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard S. Levy, M.D.”): 17,734,255 for, 1,216,648 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 22,187,716 outstanding shares: 80% for, 5% withheld (85% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (5,648,016 for, 0 against).

FOR 92%8%
FOR: 5,648,016 (92.3%)ABSTAIN: 470,274 (7.7%)
Largest asset managers voting on “Re-election of Class III directors: Richard Levy, M.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 1510For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price00 369,8820Abstain
State Street360,4140 00For
BlackRock330,9400 00For
Erste Asset Management GmbH164,4000 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable27,6120 22,7240For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust27,8900 8,9030For
Brighthouse25,7150 9,3350For
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial17,3750 6,1250For
MERIDIAN FUND INC23,4770 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

7. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-20.

Combines 6 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 20,230,193AGAINST: 179,959

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 20,230,193 for, 179,959 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 22,187,716 outstanding shares: 91% for, 0.9% against (92% of the company cast a for/against vote).

The 81 asset managers below cast 99.5% of the shares they voted on this item FOR (5,914,604 for, 23,961 against).

FOR 99.5%
FOR: 5,914,604 (99.6%)AGAINST: 23,961 (0.4%)ABSTAIN: 1,407 (0.0%)
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,8740 00For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price369,8820 00For
State Street360,290124 00For
BlackRock330,9400 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable50,3360 00For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust27,8908,903 00For
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial23,5000 00For
MERIDIAN FUND INC23,4770 00For
Putnam22,8700 00For
New York Life17,9871,673 00For

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

100% fund support · no official result

FOR 38%1-YEAR 45.6%ONE YEAR 17%

The 11 asset managers below cast 100% of the shares they voted on this item FOR (164,712 for, 0 against).

FOR: 164,712 (37.9%)1-YEAR: 198,391 (45.6%)ONE YEAR: 72,057 (16.6%)1 YEAR: 4 (0.0%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.00 001-Year
Erste Asset Management GmbH164,4000 00For
GROUPAMA ASSET MANAGMENT00 00One Year
Brighthouse00 00One Year
JPMorgan00 00One Year
VALUED ADVISERS TRUST00 00One Year
PRINCETON CAPITAL MANAGEMENT LLC2390 00For
Desjardins Global Asset Management Inc.00 00One Year
TD ASSET MANAGEMENT INC730 00For
Coyle Financial Counsel LLC00 001 Year
SIERRA SUMMIT ADVISORS LLC00 001 Year

9. Ratify PricewaterhouseCoopers LLP as Auditors

AUDIT-RELATED

Meeting held 2025-06-20.

95% fund support · no official result

10%ONE YEAR 89%

The 3 asset managers below cast 95% of the shares they voted on this item FOR (19,220 for, 1,000 against).

FOR: 19,220 (10.4%)AGAINST: 1,000 (0.5%)ONE YEAR: 164,400 (89.0%)
Largest asset managers voting on “Ratify PricewaterhouseCoopers LLP as Auditors” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH00 00One Year
Brighthouse19,2200 00For
VALUED ADVISERS TRUST01,000 00Against

10. 14A Executive Compensation Vote Frequency

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-20.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (6,302 for, 0 against).

FOR: 6,302 (100.0%)ABSTAIN: 1 (0.0%)
Largest asset managers voting on “14A Executive Compensation Vote Frequency” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Simplify Exchange Traded Funds6,3020 00For
MARCO INVESTMENT MANAGEMENT LLC00 10Abstain

11. Advisory Vote to Ratify Named Executive Officers' Compensation

COMPENSATIONMajority of the votes cast: yes

Meeting held 2024-06-25 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 15,585,020AGAINST: 781,212

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”): 15,585,020 for, 781,212 against, per its Form 8-K filed 2024-06-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 22,187,716 outstanding shares: 70% for, 4% against (74% of the company cast a for/against vote).

The 2 asset managers below cast 99.3% of the shares they voted on this item FOR (958 for, 6 against).

FOR 99.3%
FOR: 958 (99.4%)AGAINST: 6 (0.6%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Brighthouse9580 00For
COLDSTREAM CAPITAL MANAGEMENT INC06 00Against

Largest Madrigal Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked by the number of Madrigal Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 22,187,716 shares outstanding at the time of that meeting.

Top Madrigal Pharmaceuticals, Inc. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 8.99%
2BAKER BROS. ADVISORS LP 8.90%
3Janus Henderson 8.46%
4Vanguard 8.26%
5JANUS INVESTMENT FUND 6.33%
6State Street 4.66%
7T. Rowe Price 3.94%
8BlackRock 3.60%
9Fidelity 2.59%
10GEODE CAPITAL MANAGEMENT, LLC 1.76%

Reported Madrigal Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Madrigal Pharmaceuticals, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Julian C. Baker 10.11% DEF14A
Paul Friedman, M.D. 9.53% DEF14A
JANUS HENDERSON GROUP PLC 9.10% 13G
Paul A Friedman, M.D. 8.18% 13D
Rebecca Taub, M.D. 8.18% 13D
Vanguard Group 7.62% 13F
BlackRock 6.70% 13F
PAULSON & CO. INC. 6.27% 13G
State Street 3.42% 13F
FMR (Fidelity) 2.94% 13F

Percentages above are of 22,187,716 shares outstanding, as reported by Madrigal Pharmaceuticals, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Madrigal Pharmaceuticals, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Madrigal Pharmaceuticals, Inc.'s shareholder meeting held 2025-06-20, in the 2024-2025 proxy season, 331 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,737 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote to approve executive compensation — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Madrigal Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-20.

Madrigal Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.